Stephen Falchek
Neurology with Special Qualifications in Child Neurology · Wilmington, DENPI 1932290228
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,401 of the $6,418 with a category attached, or 68.6%. 22 manufacturers reported payments, led by Merck at 24.9% of the total. Reporting peaked in 2024 at $2,632 and has fallen 84.8% since, to $399 in 2025.
Across 96 payments — averaging $66.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Livanova USA, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- SK Life Science, Inc.$490
- Greenwich Biosciences, Inc.$314
- UCB, Inc.$234
- plus $1K from 16 others
Across 56 payments — averaging $1210.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$34K
- Jazz Pharmaceuticals Inc.$20K
- Biohaven Pharmaceutical Holding Company Ltd.$14K
What the payments were for
- Consulting fees$1,60025%
- Travel & lodging$4046%
- Food & beverage$4,40169%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $1,600 |
| Livanova USA, Inc. | 16 | $1,580 |
| Jazz Pharmaceuticals Inc. | 14 | $1,170 |
| SK Life Science, Inc. | 7 | $490 |
| Greenwich Biosciences, Inc. | 6 | $314 |
| UCB, Inc. | 7 | $234 |
| Neurelis, Inc. | 7 | $197 |
| Sumitomo Pharma America, Inc. | 8 | $188 |
| Ironshore Pharmaceuticals Inc. | 10 | $139 |
| Biomarin Pharmaceutical Inc. | 1 | $120 |
| Travere Therapeutics, Inc. | 1 | $120 |
| Tris Pharma Inc | 4 | $56 |
| Acadia Pharmaceuticals Inc | 3 | $48 |
| Eisai Inc. | 2 | $40 |
| Neos Therapeutics, LP | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| AbbVie | 1 | $19 |
| Kaleo, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Aquestive Therapeutics, Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Sentynl Therapeutics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,101
- Epidiolex$807
- Briviact$130
- VALTOCO$123
- Brineura$120
- (815) Thiola$120
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$111
How this compares
Too few neurology with special qualifications in child neurology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Wilmington
- Harry ChuganiWilmington$69K
- Lily TranWilmington$5K
- Mena ScavinaWilmington$5K
- Badal JainWilmington$2K
- Sumair HusainWilmington$443
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.